dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tan, Benjamin |
dc.contributor.author | Khattak, Adnan |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Kelly, Karen |
dc.contributor.author | Rich, Patricia |
dc.contributor.author | Wang, Ding |
dc.date.accessioned | 2022-02-21T09:47:35Z |
dc.date.available | 2022-02-21T09:47:35Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Target Oncol. 2021 Jul;16:435–446. |
dc.identifier.issn | 1776-260X |
dc.identifier.uri | https://hdl.handle.net/11351/7043 |
dc.description | Adenocarcinoma esofàgic; Bintrafusp Alfa |
dc.description.sponsorship | This trial was funded by Merck KGaA, Darmstadt, Germany, and is part of an alliance between Merck KGaA and GlaxoSmithKline. Merck KGaA provided the study drug and worked with investigators on the trial design and plan, collection and analysis of data, and interpretation of results. Funding for a professional medical writer with access to the data was provided by Merck KGaA and GlaxoSmithKline. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Targeted Oncology;16 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Esòfag - Malalties |
dc.subject | Càncer - Tractament |
dc.subject | Citocines - Immunologia |
dc.subject.mesh | Esophageal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Transforming Growth Factor beta |
dc.subject.mesh | /administration & dosage |
dc.title | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s11523-021-00809-2 |
dc.subject.decs | neoplasias del esófago |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | factor de crecimiento transformador beta |
dc.subject.decs | /administración & dosificación |
dc.relation.publishversion | https://doi.org/10.1007/s11523-021-00809-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tan B] Washington University School of Medicine, St Louis, MO, USA. [Khattak A] Fiona Stanley Hospital, Perth, WA, Australia. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain. [Kelly K] University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. [Rich P] Cancer Treatment Centers of America, Atlanta, GA, USA. Piedmont Healthcare, Atlanta, GA, USA. [Wang D] Henry Ford Cancer Institute, Detroit, MI, USA |
dc.identifier.pmid | 34009501 |
dc.identifier.wos | 000652087400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |